Collection of Blood From Patients With Prostate Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2016 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )
ClinicalTrials.gov Identifier:
NCT00923221
First received: June 17, 2009
Last updated: May 11, 2016
Last verified: April 2016

June 17, 2009
May 11, 2016
February 2007
Not Provided
Acquisition and longitudinal analysis of genomic DNA from patients with prostate cancer to aid in understanding the mechanisms of prostate carcinogenesis and progression [ Time Frame: Study duration ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00923221 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Collection of Blood From Patients With Prostate Cancer
Collection of Blood From Patients With Prostate Cancer

Background:

  • It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but genetics likely plays an important role.
  • Genes contain the hereditary information that is passed down from parents to children. Although everyone has the same set of genes, individuals can have different forms of the same gene.
  • Differences in genes may explain, at least in part, why some people develop a more aggressive form of prostate cancer than others.

Objectives:

-To obtain blood samples from patients with prostate cancer to try to identify gene differences associated with progression to the androgen independent state.

Eligibility:

-All patients participating in NCI prostate cancer protocols.

Design:

  • Patients with prostate cancer are evaluated in the NCI s Medical Oncology Clinic.
  • Blood samples are collected at the initial visit or at follow-up visits.
  • DNA (genetic material) and white blood cells are extracted from these samples to be used for genotyping and establishment of cell lines.
  • Gene variations are correlated with prostate cancer prognosis and prognostic indicators.

Objectives:

To obtain blood samples from patients with prostate cancer for genotyping analyses.

Eligibility:

All patients seen in the NCI prostate cancer clinic are eligible.

Design:

Patients with a prior diagnosis of prostate cancer will be evaluated in the GMB Clinic, NCI. Blood samples may be collected at the initial visit or at follow-up visits. Genomic DNA and white blood cells will each be extracted from these samples to be utilized for genotyping and establishment of individual cell lines. Genetic variance will be correlated with prostate cancer prognosis (i.e. time from diagnosis to death) and prognostic indicators (i.e. histological tumor grade). Healthy controls will not be compared and no correlations will be made with prostate cancer susceptibility.

Observational
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Not Provided
Not Provided
Prostatic Neoplasms
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
1000
Not Provided
Not Provided
  • INCLUSION CRITERIA:

Patients 18 years of age and older are eligible.

Patients with a diagnosis of prostate cancer are eligible.

EXCLUSION CRITERIA:

Children are not eligible.

Male
18 Years to 100 Years   (Adult, Senior)
No
Contact: William D Figg, Pharm.D. (301) 402-3622 wdfigg@helix.nih.gov
United States
 
NCT00923221
070100, 07-C-0100
Not Provided
Not Provided
Not Provided
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not Provided
Principal Investigator: William D Figg, Pharm.D. National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
April 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP